221 related articles for article (PubMed ID: 33883561)
21. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
[TBL] [Abstract][Full Text] [Related]
22. Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft.
Natarajan A; Ramachandran B; Gopisetty G; Jayavelu S; Sundersingh S; Rajkumar T
Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):361-371. PubMed ID: 33015747
[TBL] [Abstract][Full Text] [Related]
23. Chloroquine Combined With Rapamycin Arrests Tumor Growth in a Patient-derived Orthotopic Xenograft (PDOX) Mouse Model of Dedifferentiated Liposarcoma.
Masaki N; Aoki Y; Kubota Y; Obara K; Miyazaki J; Hoffman RM
In Vivo; 2022; 36(6):2630-2637. PubMed ID: 36309387
[TBL] [Abstract][Full Text] [Related]
24. Pazopanib regresses a doxorubicin-resistant synovial sarcoma in a patient-derived orthotopic xenograft mouse model.
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Higuchi T; Singh SR; Tsuchiya H; Hoffman RM
Tissue Cell; 2019 Jun; 58():107-111. PubMed ID: 31133237
[TBL] [Abstract][Full Text] [Related]
25. Osteosarcoma Patient-derived Orthotopic Xenograft (PDOX) Models Used to Identify Novel and Effective Therapeutics: A Review.
Higuchi T; Igarashi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Bouvet M; Tsuchiya H; Hoffman RM
Anticancer Res; 2021 Dec; 41(12):5865-5871. PubMed ID: 34848441
[TBL] [Abstract][Full Text] [Related]
26. A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatinum-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
Igarashi K; Kawaguchi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Higuchi T; Taniguchi Y; Yonezawa H; Araki Y; Morinaga S; Misra S; Nelson SD; Dry SM; Li Y; Odani A; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(3):217-223. PubMed ID: 32345663
[TBL] [Abstract][Full Text] [Related]
27. Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways.
Zeng X; Liu S; Yang H; Jia M; Liu W; Zhu W
J Pharm Pharmacol; 2023 Nov; 75(11):1405-1417. PubMed ID: 37498992
[TBL] [Abstract][Full Text] [Related]
28. Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Miyake K; Kiyuna T; Kawaguchi K; Higuchi T; Oshiro H; Zhang Z; Wangsiricharoen S; Razmjooei S; Li Y; Nelson SD; Murakami T; Hiroshima Y; Matsuyama R; Bouvet M; Chawla SP; Singh SR; Endo I; Hoffman RM
Cancer Chemother Pharmacol; 2019 May; 83(5):809-815. PubMed ID: 30758647
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Anticancer Res; 2019 Aug; 39(8):4079-4084. PubMed ID: 31366491
[TBL] [Abstract][Full Text] [Related]
30. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
Wang YT; Tang F; Hu X; Zheng CX; Gong TJ; Zhou Y; Luo Y; Min L
IUBMB Life; 2020 Oct; 72(10):2146-2153. PubMed ID: 33448097
[TBL] [Abstract][Full Text] [Related]
31. A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model.
Kiyuna T; Tome Y; Murakami T; Miyake K; Igarashi K; Kawaguchi K; Oshiro H; Higuchi T; Miyake M; Sugisawa N; Zhang Z; Razmjooei S; Wangsiricharoen S; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Eckardt MA; Singh AS; Chawla S; Kanaya F; Eilber FC; Singh SR; Zhao M; Hoffman RM
Biochem Biophys Res Commun; 2018 Nov; 505(3):733-739. PubMed ID: 30292411
[TBL] [Abstract][Full Text] [Related]
32. The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing ανβ3 integrin in chick embryo and nude mouse models.
Tome Y; Kimura H; Sugimoto N; Tsuchiya H; Kanaya F; Bouvet M; Hoffman RM
Oncotarget; 2016 Dec; 7(52):87031-87036. PubMed ID: 27894082
[TBL] [Abstract][Full Text] [Related]
33. A Novel Orthotopic Mouse Model of Lung Metastasis Using Fluorescent Patient-derived Osteosarcoma Cells.
Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Park JH; Zhang Z; Razmjooei S; Kanaya F; Nishida K; Hoffman RM
Anticancer Res; 2021 Feb; 41(2):635-640. PubMed ID: 33517267
[TBL] [Abstract][Full Text] [Related]
34. Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma.
Igarashi K; Kawaguchi K; Li S; Han Q; Tan Y; Murakami T; Kiyuna T; Miyake K; Miyake M; Singh AS; Eckardt MA; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Singh SR; Eilber FC; Hoffman RM
Cancer Lett; 2018 Mar; 417():168-173. PubMed ID: 29306021
[TBL] [Abstract][Full Text] [Related]
35. Eribulin Inhibits Osteosarcoma in a Clinically-accurate Bone-tumor-insertion PDOX Mouse Model.
Wu NF; Yamamoto J; Aoki Y; Bouvet M; Hoffman RM
Anticancer Res; 2021 Apr; 41(4):1779-1784. PubMed ID: 33813382
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
[TBL] [Abstract][Full Text] [Related]
37. Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Miyake K; Murakami T; Kiyuna T; Igarashi K; Kawaguchi K; Li Y; Singh AS; Dry SM; Eckardt MA; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Endo I; Eilber FC; Hoffman RM
J Cell Biochem; 2018 Jan; 119(1):967-972. PubMed ID: 28681998
[TBL] [Abstract][Full Text] [Related]
38. Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.
Igarashi K; Kawaguchi K; Murakami T; Kiyuna T; Miyake K; Nelson SD; Dry SM; Li Y; Yanagawa J; Russell TA; Singh AS; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
Cell Cycle; 2017 Jun; 16(12):1164-1170. PubMed ID: 28494180
[TBL] [Abstract][Full Text] [Related]
39. Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models.
Kawaguchi K; Igarashi K; Miyake K; Kiyuna T; Miyake M; Singh AS; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Singh SR; Eilber FC; Hoffman RM
J Drug Target; 2019 Feb; 27(2):211-216. PubMed ID: 30024282
[TBL] [Abstract][Full Text] [Related]
40. Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study.
Wang Q; Zhong YJ; Yuan JP; Shao LH; Zhang J; Tang L; Liu SP; Hong YP; Firestone RA; Li Y
J Transl Med; 2013 Aug; 11():192. PubMed ID: 23961994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
